Aptorum Group Ltd Cl A (APM) Stock Price, Quote & News

Company Profile

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylo...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 8092 9299

Website: www.aptorumgroup.com

Address:

17 Hanover Square, London, United Kingdom

NinjaRai Aug. 12 at 7:56 AM

$APM $CHSN $PLBL

0 · Reply

SpartanVI Aug. 12 at 7:33 AM

Today's watchlist $CHSN Broke all resistance and touched new highs since the big drop Key break .12$ potential. 15+ $APM Broke Downtrend Merger Catalyst Q4 Nice move yesterday $PLBL Broke 12$ yesterday Needs more key is 13$ break here

0 · Reply

Savior79 Aug. 11 at 6:59 PM

$APM we need the big guns to buy in!! Only small ones are adding on and we are moving uk slowly…… I can just imagine if a couple of big ones buy in the price would 🚨🚨🚨🚨🚨🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

Savior79 Aug. 11 at 6:48 PM

$APM we are so close to blast off!!! Load up and thank me later!!! If you follow me load up so we can ride money train!!!

0 · Reply

SpartanVI Aug. 11 at 3:58 PM

$APM above 1.5 gets really interesting

0 · Reply

SpartanVI Aug. 11 at 2:23 PM

$APM will have a move very soon

0 · Reply

NinjaRai Aug. 11 at 7:59 AM

$APM $RVYL

0 · Reply

SpartanVI Aug. 10 at 11:51 AM

Premarket watch $RVYL Nice slaps Friday bottom penny Needs to Hold .35 key to break .40 $PLBL key 12 break potential-15$+ $APM Merger Ahead they have some other catalyst aswell ww

0 · Reply

edizank Aug. 8 at 9:52 PM

$APM $APM chin chan chun.pile of big shit. it is going to below 1$ .i hope that one day you lose your everyrging. ihope you catch heavy sicknes mr huen.

0 · Reply

edizank Aug. 7 at 3:07 PM

$APM CEO İS Chung Yuen huen. you should not expect anything from this empty company.These stock are just in stock market for cheating.

0 · Reply

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Jul 16, 2025, 8:38 AM EDT - 26 days ago

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Apr 16, 2025, 12:27 PM EDT - 4 months ago

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 8, 2025, 11:30 AM EST - 7 months ago

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

Jan 2, 2025, 10:55 AM EST - 7 months ago

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Dec 20, 2024, 4:00 PM EST - 8 months ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Apr 30, 2024, 9:15 AM EDT - 1 year ago

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Dec 22, 2023, 4:30 PM EST - 1 year ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Dec 21, 2023, 4:30 PM EST - 1 year ago

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Nov 16, 2023, 11:00 AM EST - 1 year ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aug 10, 2023, 2:57 AM EDT - 2 years ago

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Jun 22, 2023, 8:00 AM EDT - 2 years ago

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Jun 9, 2023, 4:30 PM EDT - 2 years ago

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

May 5, 2023, 4:31 PM EDT - 2 years ago

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

May 1, 2023, 8:00 AM EDT - 2 years ago

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

Apr 28, 2023, 9:44 AM EDT - 2 years ago

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Mar 17, 2023, 8:15 AM EDT - 2 years ago

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ASPI

Mar 3, 2023, 7:30 AM EST - 2 years ago

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Mar 3, 2023, 7:30 AM EST - 2 years ago

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Mar 2, 2023, 7:30 AM EST - 2 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Feb 10, 2023, 4:30 PM EST - 2 years ago

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Feb 6, 2023, 10:08 AM EST - 2 years ago

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Jan 20, 2023, 8:22 AM EST - 2 years ago

Aptorum Group Announces 1-for-10 Reverse Stock Split

Jan 4, 2023, 9:00 AM EST - 2 years ago

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Dec 22, 2022, 8:00 AM EST - 2 years ago

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Dec 16, 2022, 8:00 AM EST - 2 years ago

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Dec 9, 2022, 7:00 AM EST - 2 years ago

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Nov 25, 2022, 8:30 AM EST - 2 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Nov 25, 2022, 8:00 AM EST - 2 years ago

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Nov 18, 2022, 5:30 PM EST - 2 years ago

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Nov 8, 2022, 6:00 AM EST - 2 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Sep 30, 2022, 7:42 PM EDT - 3 years ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Sep 15, 2022, 8:07 AM EDT - 3 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Sep 15, 2022, 7:00 AM EDT - 3 years ago

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Aug 25, 2022, 8:31 PM EDT - 3 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

May 17, 2022, 8:13 AM EDT - 3 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

May 2, 2022, 8:00 AM EDT - 3 years ago

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

Apr 29, 2022, 4:00 PM EDT - 3 years ago

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

Apr 25, 2022, 9:30 AM EDT - 3 years ago

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

Apr 22, 2022, 8:00 AM EDT - 3 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Feb 11, 2022, 3:09 PM EST - 3 years ago

Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies

Jan 20, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Jan 18, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

Jan 10, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

Jan 10, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

Jan 10, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

Dec 3, 2021, 8:00 AM EST - 4 years ago

Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders

Oct 19, 2021, 8:00 AM EDT - 4 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021

NinjaRai Aug. 12 at 7:56 AM

$APM $CHSN $PLBL

0 · Reply

SpartanVI Aug. 12 at 7:33 AM

0 · Reply

Savior79 Aug. 11 at 6:59 PM

0 · Reply

Savior79 Aug. 11 at 6:48 PM

$APM we are so close to blast off!!! Load up and thank me later!!! If you follow me load up so we can ride money train!!!

0 · Reply

SpartanVI Aug. 11 at 3:58 PM

$APM above 1.5 gets really interesting

0 · Reply

SpartanVI Aug. 11 at 2:23 PM

$APM will have a move very soon

0 · Reply

NinjaRai Aug. 11 at 7:59 AM

$APM $RVYL

0 · Reply

SpartanVI Aug. 10 at 11:51 AM

Premarket watch $RVYL Nice slaps Friday bottom penny Needs to Hold .35 key to break .40 $PLBL key 12 break potential-15$+ $APM Merger Ahead they have some other catalyst aswell ww

0 · Reply

edizank Aug. 8 at 9:52 PM

$APM $APM chin chan chun.pile of big shit. it is going to below 1$ .i hope that one day you lose your everyrging. ihope you catch heavy sicknes mr huen.

0 · Reply

edizank Aug. 7 at 3:07 PM

$APM CEO İS Chung Yuen huen. you should not expect anything from this empty company.These stock are just in stock market for cheating.

0 · Reply

edizank Aug. 7 at 2:40 PM

$APM did 16 july 196m$ volume .last days only 13K$ISH volume.what a shit company. It's nothing more than stealing people's savings on difficult days.

0 · Reply

edizank Aug. 7 at 2:19 PM

$APM i would never buy chinesse stock all of them scam stay away

0 · Reply

edizank Aug. 7 at 11:25 AM

$APM see low price 16th july hish monetuö day.anymore must go un.nerd more price up? as techinacal and merge other company ‼️‼️‼️🚨🚨🚨🚨🚨

0 · Reply

TheBidenDuffleBagBoy Aug. 6 at 7:27 PM

$APM everything I’m reading is saying to wait until the 4th quarter for the merger to be complete and this stock will be a money maker

0 · Reply

Savior79 Aug. 6 at 4:31 PM

$APM end of year $5 plus definitely….💯 Thank me later 🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨

1 · Reply

edizank Aug. 6 at 3:29 PM

$APM what a pity stock !!! down down just 500K$ can spike up this!!

0 · Reply

SpartanVI Aug. 6 at 12:40 PM

$APM Merger Catalyst Will watch this one

0 · Reply

edizank Aug. 5 at 11:27 AM

$APM

0 · Reply

edizank Aug. 5 at 10:05 AM

$APM wwwww loading!!!!

0 · Reply

edizank Aug. 5 at 3:19 AM

$APM https://www.quiverquant.com/news/Aptorum+Group+Regains+Compliance+with+Nasdaq%27s+Minimum+Bid+Price+Requirement

0 · Reply

edizank Aug. 5 at 3:16 AM

$APM 💯💯💯💯🤝🤝🤝🤝🤝🤝🤝🤝On July 14, 2025 Aptorum announced that it entered into a definitive agreement for an all-stock merger transaction with DiamiR Biosciences, a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA-licensed, CAP-accredited clinical laboratory in New Haven, CT. As a result of this transaction and subject to the customary closing conditions, DiamiR Biosciences will become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger. About Aptorum Group

0 · Reply

edizank Aug. 5 at 3:09 AM

$APM 👆👆👆👆 please 🙏🙏🙏 spike 🆙🆙🆙⬆️⬆️⬆️🇺🇸🇺🇸🇺🇸🇺🇸🇬🇧🇬🇧🇬🇧🇬🇧🇬🇧🇬🇧👁️👁️👁️👁️👁️👁️👁️👁️🥇🥇🥇🥇🎯🎯🎯🎯🎯🎯🚨🚨🚨🚨🚨🚨🚨🎢🎢🎢🎢🎇🎆🌅🎇🎆🌅⏳⏳⏳⏳👍👍👍👍✅✅✅✅✅💳💳💳💳💰💰💰💰💰💵💵💵💵💵💎💎💎💎💎💎🔝🔝🔝🔝🔝🔝💣💣💣💣🧨🧨🧨🧨🧨🪬🪬🪬🪬🪬🎊🎊🎊🎊🎉🎉🎉🎉👀👀👀👀👀💯💯💯💯💯🆒🆒🆒🆒🆒🆙🆙🆙🆙🆙💥💥💥💥💥💥💥🌋🌋🌋🌋🌋📈📈📈📈🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

Market Cap	6.74M
Revenue (ttm)	0.00
Net Income (ttm)	-4.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.28

Volume	256,800
Avg Vol	4,153,508
Day's Range	N/A - N/A
Shares Out	5.35M
Stochastic %K	41%
Beta	-0.10
Analysts	Strong Buy
Price Target	$80.00